Gencurix Inc.
KOSDAQ
₩1,940.00
-1.02%
Delayed · cached 15 min
Peer comparison
| Company | Price↕ | Market Cap↕ | P/E↕ | P/B↕ | ROE %↕ | ROCE %↕ | Div yield %↕ | Valuation |
|---|---|---|---|---|---|---|---|---|
| SAMSUNG BIOLOGICS CO.,LTD. | ₩ 1,415,000.00 | ₩65조 5,017억 | 36.67 | 8.78 | 23.95 | 24.26 | — | Above FV |
| Celltrion, Inc. | ₩ 178,200.00 | ₩40조 8,661억 | 38.17 | 2.26 | 5.98 | 6.53 | 0.40 | Above FV |
| GC Biopharma Corp. | ₩ 128,300.00 | ₩1조 4,643억 | -312.93 | 1.20 | -0.38 | 3.79 | 0.90 | — |
| SAM CHUN DANG PHARM CO. LTD | ₩ 160,700.00 | ₩3조 7,616억 | 711.06 | 13.54 | 1.91 | 1.86 | 0.02 | Above FV |
| Hanmi Pharm. Co., Ltd. | ₩ 464,000.00 | ₩5조 8,836억 | 34.70 | 4.71 | 13.57 | 16.82 | 0.80 | Above FV |
| YUHAN CORPORATION | ₩ 79,400.00 | ₩5조 8,451억 | 30.55 | 2.47 | 8.22 | 4.20 | 0.50 | Above FV |
| HLB INC. | ₩ 31,450.00 | ₩4조 1,789억 | -18.72 | 9.96 | -52.69 | -17.89 | — | — |
| PharmaResearch Co., Ltd. | ₩ 342,000.00 | ₩3조 5,533억 | 22.90 | 5.15 | 23.95 | 22.97 | 0.90 | Above FV |
| ABL Bio Inc. | ₩ 66,100.00 | ₩3조 7,008억 | -90.05 | 23.55 | -24.44 | -25.65 | — | — |
| SK Bioscience Co.,Ltd | ₩ 37,250.00 | ₩2조 9,225억 | -50.82 | 1.63 | -3.21 | -4.70 | — | — |
| Hugel, Inc. | ₩ 231,000.00 | ₩2조 4,956억 | 17.69 | 2.63 | 14.82 | 20.42 | — | Above FV |
| HANALL BIOPHARMA CO.,LTD | ₩ 50,100.00 | ₩2조 5,480억 | -459.63 | 15.74 | -3.44 | -0.51 | — | — |
Price, market cap, P/E, P/B and dividend yield reflect the live quote (delayed, cached 15 min); ROE/ROCE from reported financials. The highlighted row is the current company. Click a column header to sort. Educational data only.
How to read the peer comparison
This table places the company beside others in the same industry on a few common measures. Comparison adds context that a single company's numbers cannot give on their own.
- Valuation multiples like P/E and P/B are most meaningful within the same industry, because different industries naturally trade at different levels. Comparing a company only to its peers is more useful than to the whole market.
- Return measures (ROE, ROCE) show how efficiently each company turns capital into profit. A company well ahead of or behind its peers here is worth understanding.
- No single column decides anything. A beginner reads the row across — valuation, returns, and size together — and treats the highlighted current company as one data point among its peers.
- Use the sortable headers to rank peers on any measure, but remember that "cheaper" or "higher" on one metric is a starting question, not an answer.
Educational only — not a recommendation to buy, sell, or hold any security.